Conduit Pharmaceuticals Total Revenue

As of the most recent data (June 2026), CDT shows a total revenue of $2.9B. That compares with $2.6B in the prior-year period — up 9.7% year over year. That is above the sector sector average of $1.3B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CDT's total revenue is now $2.9B (was $2.6B) — a 9.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Conduit Pharmaceuticals is outperforming or lagging.

The its sector sector average total revenue is about $1.3B. Conduit Pharmaceuticals is at $2.9B, which is higher that average. That is roughly 116.8% above the sector mean. Use the comparison chart on this page to see how CDT stacks up against individual peers as well.

Tracking CDT's total revenue over time shows whether Conduit Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $2.9B That compares with $2.6B in the prior-year period — up 9.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Conduit Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $2.9B) with ownership activity and broader fundamentals.